PatientSpotlight, by PanaceaIntelPatientSpotlight

Topic · Oncology

Access

Coverage of who can actually get diagnosis and treatment - payer dynamics, geographic variation, infrastructure constraints, and the international divergence that defines real-world access. 2 pieces on access in Oncology, newest first within each collection.

← All topics
FilterAll (58)Oncology (2)Rare Disease (8)Immunology (2)Neurology (25)Cardiometabolic (4)Respiratory (3)Women's Health (5)Mental Health (7)Ophthalmology (2)

Explained

2
ExplainedApr 26, 2026peer-reviewed · specialty-lab

ctDNA-guided treatment decisions are entering routine oncology care

Circulating tumour DNA testing has moved from research-grade tool to a routine decision aid in several oncology indications. The pathways from blood draw to clinical decision are now described well enough to plan around, even though reimbursement remains uneven.

BiomarkersDiagnosisAccess
ExplainedApr 26, 2026FDA · EMA · HTA-bodies

Why 'tumor-agnostic' approvals are reshaping reimbursement reviews

When a drug is approved for a molecular target across tumor types rather than for one cancer, the HTA review framework has to evaluate efficacy across heterogeneous indications with different unmet needs, comparators, and standard-of-care benchmarks. That has practical consequences for access timelines.

RegulatoryReimbursementTumor agnosticAccess